Sustained Complete B Cell Depletion is Associated with Rituximab Efficacy in Connective Tissue Disorders-associated Interstitial Lung Disease
Overview
Overview
Journal
RMD Open
Publisher
BMJ Publishing Group
Specialty
Rheumatology
Date
2023 Feb 8
PMID
36754549
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Goswami R, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P
. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). 2020; 60(2):557-567.
DOI: 10.1093/rheumatology/keaa550.
View
2.
Sircar G, Goswami R, Sircar D, Ghosh A, Ghosh P
. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). 2018; 57(12):2106-2113.
DOI: 10.1093/rheumatology/key213.
View
3.
Lepri G, Avouac J, Airo P, Anguita Santos F, Bellando-Randone S, Blagojevic J
. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016; 34 Suppl 100(5):181-185.
View
4.
Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K
. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. J Dermatol. 2021; 49(1):179-183.
DOI: 10.1111/1346-8138.16206.
View
5.
Vital E, Rawstron A, Dass S, Henshaw K, Madden J, Emery P
. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011; 63(3):603-8.
DOI: 10.1002/art.30152.
View